Dr. Kenneth Alleyne
About Dr. Kenneth Alleyne
Dr. Kenneth Alleyne (age 59) is a board-certified orthopedic surgeon specializing in sports medicine, practicing in Connecticut and Manhattan since 2004; he joined OneMedNet’s Board in February 2025 and serves as an independent Class III director with a term expiring at the 2026 annual meeting . He is Managing Partner of HartHaven Partners (healthcare consulting) and co-founded NextLevel Health Partners (Medicaid MCO, 2013), Zing Healthcare (Medicare Advantage, 2020), and Fizio Health (AI remote physical therapy, 2022); his education includes Williams College (B.A.), Wake Forest University (M.D.), residency at Howard University Hospital, sports medicine fellowship at Yale, and tissue engineering fellowship at Harvard-MIT HST .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Private practice (CT & NYC) | Orthopedic surgeon, sports medicine | Since 2004 | Team physician/consultant to athletic organizations |
| HartHaven Partners | Managing Partner | Since 2007 | Advises PE/VC on healthcare deals |
| NextLevel Health Partners | Co-founder | 2013–present | Medicaid managed care operations |
| Zing Healthcare | Co-founder | 2020–present | Medicare Advantage plan strategy |
| Fizio Health | Co-founder & CEO | 2022–present | AI computer vision for remote PT |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Connecticut Health Foundation | Former Chair | Prior to 2025 | Community health, governance leadership |
| University of Connecticut Health Center | Board member | Current | Academic medical governance |
| Connecticut Public Television and Radio | Board member | Since 2019 | Public media oversight |
| Louis Armstrong Educational Foundation | Board member | Current | Non-profit board |
| Student Achievement Through Opportunity | Board member | Current | Education non-profit |
Board Governance
- Committee assignments: Audit Committee Chair (current); Audit Committee met 4 times in 2024; Nominating & Corporate Governance and Compensation Committees are fully independent with chairs noted below .
- Committee composition snapshot (current): Audit—Chair: Dr. Alleyne; Members: McCraw, Kosasa; Compensation—Chair: Zeinfeld; Member: Clarke; Nominating—Chair: Casaburi; Member: Zeinfeld .
- Independence: Board determined Dr. Alleyne is independent under Nasdaq and SEC rules .
- Attendance: Board held 2 meetings in 2024 with no director under 75% attendance; four directors attended the 2024 annual meeting. (Note: Alleyne joined in Feb 2025; 2025 attendance for him not disclosed) .
- Audit Committee oversight: Cybersecurity, accounting/financial reporting, auditor independence; Audit Committee report signed by Chair Dr. Alleyne in the 2025 proxy .
Fixed Compensation
| Component | Amount/Structure | Timing | Notes |
|---|---|---|---|
| Annual director equity grant | 45,000 RSUs per full year of service | Annual | Revised policy adopted Apr 2024; grants occur annually; reimburses reasonable board meeting expenses . |
| Cash retainer | None disclosed for directors (2024 table shows $0 cash fees) | N/A | Director compensation in 2024 comprised equity awards only . |
| Committee/Chair fees | Not disclosed | N/A | No separate committee chair/membership fees disclosed . |
Individual grant details for Dr. Alleyne (joined Feb 2025) are not itemized in the 2025 proxy’s director compensation section (which covers fiscal 2024); only the policy framework is disclosed .
Performance Compensation
| Performance Vehicles | Metrics | Vesting/Conditions | Notes |
|---|---|---|---|
| None disclosed for directors | N/A | RSUs appear time-based; no PSU metrics disclosed | No TSR/EBITDA/ESG targets disclosed for director grants . |
Other Directorships & Interlocks
| Category | Details |
|---|---|
| Current public company boards | None disclosed . |
| Non-profit/academic boards | University of Connecticut Health Center; CT Public Television and Radio; Louis Armstrong Educational Foundation; Student Achievement Through Opportunity . |
| Interlocks with ONMD customers/suppliers | None disclosed; proxy’s related party transactions list does not include Alleyne . |
Expertise & Qualifications
- Deep clinical expertise in orthopedics and sports medicine with health-tech entrepreneurship (AI remote PT, payor models), aligning with ONMD’s healthcare IT/data orientation .
- Governance experience across health foundation and academic boards; complements audit oversight with sector literacy; Audit Committee retains an “financial expert” (McCraw), providing technical finance depth alongside Alleyne’s chair role .
Equity Ownership
| Metric | Value |
|---|---|
| Shares beneficially owned (Oct 23, 2025) | 0 |
| Shares outstanding (record date) | 51,157,069 |
| Ownership as % of outstanding | 0.00% (calculated from disclosed values) |
| Vested vs unvested | Not disclosed for Alleyne . |
| Pledged or hedged shares | Hedging/pledging transactions prohibited by policy . |
| Ownership guidelines | Not disclosed . |
Insider Trades
| Filing Date | Transaction Date | Type | Shares | Price | Post-transaction Holding | Notes |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | No Form 4 filings found for “Kenneth Alleyne” at ONMD from 2024-01-01 to 2025-11-20 (source: insider-trades skill output). |
Governance Assessment
- Positives:
- Independent director with sector-relevant clinical and healthcare IT/startup experience; chairs Audit Committee, which oversees cybersecurity and financial reporting risks .
- Presence of an Audit Committee “financial expert” (McCraw) mitigates technical finance risk under Alleyne’s chair leadership .
- Clawback policy adopted in Nov 2024; broad hedging/pledging prohibitions enhance alignment and risk controls .
- Watch items / potential red flags:
- Ownership alignment: 0 shares beneficially owned as of Oct 23, 2025; absence of disclosed holdings may be perceived as limited “skin-in-the-game” versus peers (policy grants RSUs annually, but Alleyne’s individual grants not itemized) .
- Audit chair not designated as the committee’s “financial expert” (role held by McCraw); workable but some investors prefer chairs with formal financial expert designation .
- Related-party financing activity at ONMD prominently involves other insiders (Yu, Kosasa); no involvement by Alleyne is disclosed, but continued monitoring for any evolving ties is prudent .
Related-Party Transactions (Alleyne-specific)
- No ONMD related-party transactions disclosed involving Dr. Alleyne; 2023–2025 transactions list involves other insiders (PIPE notes, loans, conversions) and were board-approved under policy .
Committee Snapshot (Detail)
| Committee | Chair | Members | Meetings (2024) |
|---|---|---|---|
| Audit | Dr. Kenneth Alleyne | McCraw; Kosasa | 4 |
| Compensation | Andrew Zeinfeld | Clarke | 1 |
| Nominating & Corporate Governance | Eric Casaburi | Zeinfeld | 2 |
Annual Meeting Voting (context)
- 2024 director elections and auditor ratification passed with strong support; provides context for board stability (pre-Alleyne tenure) .
Overall: Alleyne’s independence, clinical/health-tech expertise, and audit chair role are positives for risk oversight and sector alignment. The primary watch item is low disclosed ownership (0 shares) as of the record date; investors may prefer confirmation of RSU grants and any subsequent holdings to assess alignment. Continued monitoring of audit committee effectiveness and any developing related-party ties remains advisable .